BMG LABTECH Invests 4.5 Million Euro in Headquarters Site Expansion
News Aug 30, 2016
BMG LABTECH has recorded a rapid increase in revenue over the past years. A new company building provides the additional capacity required for the company's anticipated business growth over the longer term. The expansion is a necessary response to the global demand for BMG LABTECH products and technologies made in Germany.
The new building is designed to double the manufacturing area and provide new space for warehouse capacities, research and development and the planned job growth. The new capabilities will ensure that BMG LABTECH can continue to meet demand while also developing new products to suit customer needs.
BMG LABTECH is at the forefront of technology offering microplate readers for life sciences applications and high-throughput screening. The company is on a steady course of growth due to continuous development of innovative and unique technologies over the past 25 years.
BMG LABTECH employs 110 people at its headquarters and its five subsidiaries in Australia, France, UK, Japan, and the US. More than 50 distributors provide additional product, technical and software support all over the world.
The Smoke Screen - Sensor Arms Race is OnNews
The military uses smoke grenades in dangerous situations to provide cover for people and tanks on the move. But increasingly, sensors can now go beyond the visible range into the infrared (IR) region of the spectrum. Today, researchers report developing a new kind of smoke that obscures both visible and IR detection.READ MORE
Catalyst Can Degrade Alzheimer's-Related Amyloid Peptide Under Near-Infrared LightNews
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Αβ) under near-infrared (NIR) light irradiation has been developed.READ MORE
Understanding 'Disease Mechanisms' of ALSNews
Researchers are making strides in understanding the disease mechanism of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. They recently found that ubiquitin eliminates droplets of Ubiquilin-2 (UBQLN2) in solution. The discovery is noteworthy because UBQLN2 is a protein-encoding gene, mutations to which cause ALS and various types of dementia.READ MORE